BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Greenbaum U, Strati P, Saliba RM, Torres J, Rondon G, Nieto Y, Hosing C, Srour SA, Westin J, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Flowers CR, Tummala S, Ramdial JL, Yalniz FF, Hawkins M, Rezvani K, Champlin RE, Shpall EJ, Neelapu SS, Kebriaei P, Ahmed S. CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv 2021;5:2799-806. [PMID: 34264268 DOI: 10.1182/bloodadvances.2021004575] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
Number Citing Articles
1 Vic S, Lemoine J, Armand P, Lemonnier F, Houot R. Transplant-ineligible but chimeric antigen receptor T-cells eligible: a real and relevant population. Eur J Cancer 2022;175:246-53. [PMID: 36166850 DOI: 10.1016/j.ejca.2022.08.019] [Reference Citation Analysis]
2 Talleur AC, Myers R, Annesley C, Shalabi H. Chimeric Antigen Receptor T-cell Therapy: Current Status and Clinical Outcomes in Pediatric Hematologic Malignancies. Hematol Oncol Clin North Am 2022;36:701-27. [PMID: 35780062 DOI: 10.1016/j.hoc.2022.03.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Tan JY, Low MH, Chen Y, Lim FLWI. CAR T Cell Therapy in Hematological Malignancies: Implications of the Tumor Microenvironment and Biomarkers on Efficacy and Toxicity. IJMS 2022;23:6931. [DOI: 10.3390/ijms23136931] [Reference Citation Analysis]
4 Kulkarni UP, Pai AA, Ml K, Selvarajan S, Lionel S, Devasia AJ, Korula A, Na F, Sindhuvi E, Abraham A, Srivastava A, Mathews V, George B, Balasubramanian P. EASIX measured pre-transplantation predicts transplant-related mortality in patients with thalassemia major undergoing transplantation with thiotepa, treosulfan, and fludarabine conditioning. Transplantation and Cellular Therapy 2022. [DOI: 10.1016/j.jtct.2022.05.001] [Reference Citation Analysis]
5 Rejeski K, Perez A, Iacoboni G, Penack O, Bücklein V, Jentzsch L, Mougiakakos D, Johnson G, Arciola B, Carpio C, Blumenberg V, Hoster E, Bullinger L, Locke FL, von Bergwelt-Baildon M, Mackensen A, Bethge W, Barba P, Jain MD, Subklewe M. The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL. J Immunother Cancer 2022;10:e004475. [PMID: 35580927 DOI: 10.1136/jitc-2021-004475] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Korell F, Penack O, Mattie M, Schreck N, Benner A, Krzykalla J, Wang Z, Schmitt M, Bullinger L, Müller-tidow C, Dreger P, Luft T. EASIX and Severe Endothelial Complications After CD19-Directed CAR-T Cell Therapy—A Cohort Study. Front Immunol 2022;13:877477. [DOI: 10.3389/fimmu.2022.877477] [Reference Citation Analysis]
7 Grant SJ, Grimshaw AA, Silberstein J, Murdaugh D, Wildes TM, E Rosko A, Giri S. Clinical presentation, risk factors, and outcomes of immune effector cell-associated neurotoxicity syndrome following CAR-T cell therapy: A Systematic Review. Transplantation and Cellular Therapy 2022. [DOI: 10.1016/j.jtct.2022.03.006] [Reference Citation Analysis]
8 Zhao F, Zhang S, Zhang S. Editorial: Platelets in Disease: From Biomarkers Discovery to Therapeutic Targets. Front Pharmacol 2022;13:860652. [DOI: 10.3389/fphar.2022.860652] [Reference Citation Analysis]
9 Nydegger A, Novak U, Kronig MN, Legros M, Zeerleder S, Banz Y, Bacher U, Pabst T. Transformed Lymphoma Is Associated with a Favorable Response to CAR-T-Cell Treatment in DLBCL Patients. Cancers (Basel) 2021;13:6073. [PMID: 34885182 DOI: 10.3390/cancers13236073] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
10 Tvedt THA, Vo AK, Bruserud Ø, Reikvam H. Cytokine Release Syndrome in the Immunotherapy of Hematological Malignancies: The Biology behind and Possible Clinical Consequences. J Clin Med 2021;10:5190. [PMID: 34768710 DOI: 10.3390/jcm10215190] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
11 Caimi PF, Pacheco Sanchez G, Sharma A, Otegbeye F, Ahmed N, Rojas P, Patel S, Kleinsorge Block S, Schiavone J, Zamborsky K, Boughan K, Hillian A, Reese-Koc J, Maschan M, Dropulic B, Sekaly RP, de Lima M. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma. Front Immunol 2021;12:745320. [PMID: 34712233 DOI: 10.3389/fimmu.2021.745320] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
12 Al-Juhaishi T, Ahmed S. CAR-T in B-Cell Lymphomas: The Past, Present, and Future. Clin Lymphoma Myeloma Leuk 2021:S2152-2650(21)02383-1. [PMID: 34782260 DOI: 10.1016/j.clml.2021.10.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]